All In Biotech

Drug Trial Radar · NCT05739435

Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis

A Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Patients With Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

165

Actual

Start

Jan 17, 2023

Primary completion

Dec 1, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Alumis IncIndustry
Sponsor type
Industry
First posted
Feb 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.

Conditions

  • Plaque Psoriasis

Interventions

  • envudeucitinibDrug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability of long-term ESK-001 treatmentTime frame: Approximately 3 years

Locations

38 sites in 2 countries. Site status is shown where the registry gives one.

  • Investigator Site # 1029

    Birmingham, Alabama

  • Investigator Site #1001

    Phoenix, Arizona

  • Investigator Site # 1023

    Rogers, Arkansas

  • Investigator Site #1021

    Encinitas, California

  • Investigator Site #1018

    Los Angeles, California

  • Investigator Site #1007

    Santa Monica, California

  • Investigator Site #1002

    Sherman Oaks, California

  • Investigator site # 1030

    Fort Lauderdale, Florida

  • Investigator Site #1025

    Hialeah, Florida

  • Investigator site # 1028

    Miami, Florida

  • Investigator Site # 1013

    Tampa, Florida

  • Investigator Site #1035

    Macon, Georgia

  • Investigator Site #1043

    Sandy Springs, Georgia

  • Investigator Site #1005

    Rolling Meadows, Illinois

  • Investigator Site # 1011

    Columbus, Indiana

  • Investigator Site #1027

    South Bend, Indiana

  • Investigator SIte#1036

    Overland Park, Kansas

  • Investigator Site #1017

    Owensboro, Kentucky

  • Investigator Site #1026

    Rockville, Maryland

  • Investigator Site #1010

    Clarkston, Michigan

  • Investigator Site #1031

    New Brighton, Minnesota

  • Investigator Site #1033

    Norman, Oklahoma

  • Investigator Site #1019

    Portland, Oregon

  • Investigator Site #1022

    Philadelphia, Pennsylvania

  • Investigator Site # 1012

    Rapid City, South Dakota

  • Investigator Site #1015

    Houston, Texas

  • Investigator Site # 1006

    San Antonio, Texas

  • Investigator Site # 1041

    South Jordan, Utah

  • Investigator Site #2001

    Edmonton, Alberta, Canada

  • Investigator Site # 2008

    Surrey, British Columbia, Canada

  • Investigator Site #2003

    Winnipeg, Manitoba, Canada

  • Investigator Site #2006

    London, Ontario, Canada

  • Investigator Site # 2004

    Mississauga, Ontario, Canada

  • Investigator Site # 2007

    North Bay, Ontario, Canada

  • Investigator Site #2005

    Oakville, Ontario, Canada

  • Investigator Site #2009

    Toronto, Ontario, Canada

  • Investigator Site # 2002

    Waterloo, Ontario, Canada

  • Investigator Site # 2010

    Québec, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.